The stock of Cryolife Inc (NYSE:CRY) hit a new 52-week high and has $23.73 target or 22.00% above today’s $19.45 share price. The 6 months bullish chart indicates low risk for the $657.69M company. The 1-year high was reported on Nov, 17 by Barchart.com. If the $23.73 price target is reached, the company will be worth $144.69 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 47,707 shares traded hands. Cryolife Inc (NYSE:CRY) has risen 60.55% since April 15, 2016 and is uptrending. It has outperformed by 55.93% the S&P500.
Cryolife Inc (NYSE:CRY) Ratings Coverage
Out of 2 analysts covering Cryolife (NYSE:CRY), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cryolife has been the topic of 2 analyst reports since April 13, 2016 according to StockzIntelligence Inc. Lake Street initiated the stock with “Buy” rating in Wednesday, June 15 report. The stock of Cryolife Inc (NYSE:CRY) has “Buy” rating given on Wednesday, April 13 by Canaccord Genuity.
According to Zacks Investment Research, “CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The company’s BioGlue surgical adhesive, the company marked in the European Union for use in vascular and pulmonary sealing and repair, is distributed throughout Europe. The company also manufactures CryoLife- O’Brien and CryoLife-Ross stentless porcine heart valves which are distributed within the European Community. (PRESS RELEASE)”
Insitutional Activity: The institutional sentiment increased to 2.19 in Q2 2016. Its up 0.45, from 1.74 in 2016Q1. The ratio improved, as 8 funds sold all Cryolife Inc shares owned while 24 reduced positions. 20 funds bought stakes while 50 increased positions. They now own 19.57 million shares or 9.07% more from 17.94 million shares in 2016Q1.
Arizona State Retirement System last reported 0% of its portfolio in the stock. Renaissance Techs owns 795,500 shares or 0.02% of their US portfolio. Paloma Ptnrs Management Com holds 0% of its portfolio in Cryolife Inc (NYSE:CRY) for 13,207 shares. Price T Rowe Assoc Md holds 0% of its portfolio in Cryolife Inc (NYSE:CRY) for 14,550 shares. Texas Permanent School Fund accumulated 0% or 19,701 shares. Leisure Capital holds 0.25% of its portfolio in Cryolife Inc (NYSE:CRY) for 18,821 shares. The Pennsylvania-based Nationwide Fund Advsrs has invested 0% in Cryolife Inc (NYSE:CRY). Bridgeway Mgmt last reported 0.02% of its portfolio in the stock. Kcg holds 0.01% or 40,958 shares in its portfolio. The Florida-based Ladenburg Thalmann Fin Service Inc has invested 0% in Cryolife Inc (NYSE:CRY). The Minnesota-based Thrivent For Lutherans has invested 0% in Cryolife Inc (NYSE:CRY). Invesco last reported 0% of its portfolio in the stock. State Common Retirement Fund accumulated 39,566 shares or 0% of the stock. Blackrock Advisors Ltd Liability Company last reported 14,823 shares in the company. Teachers, a New York-based fund reported 50,398 shares.
Insider Transactions: Since June 1, 2016, the stock had 0 insider purchases, and 2 selling transactions for $143,600 net activity. 2,000 shares with value of $28,000 were sold by RONALD C ELKINS on Tuesday, July 26. McCall Ronald D also sold $115,600 worth of Cryolife Inc (NYSE:CRY) on Wednesday, June 1.
More notable recent Cryolife Inc (NYSE:CRY) news were published by: Prnewswire.com which released: “CryoLife Appoints James McDermid as Chief Human Resources Officer” on September 06, 2016, also Prnewswire.com with their article: “CryoLife Announces Definitive Agreement to Acquire On-X Life Technologies …” published on December 22, 2015, Fool.com published: “Why Cryolife Inc’s Shares Turned Hot Today” on July 26, 2016. More interesting news about Cryolife Inc (NYSE:CRY) were released by: Prnewswire.com and their article: “James W. Bullock Joins CryoLife Board of Directors” published on October 25, 2016 as well as Prnewswire.com‘s news article titled: “CryoLife Announces Release Date and Teleconference Call Details for 2016 Third …” with publication date: October 12, 2016.
CRY Company Profile
CryoLife, Inc. (CryoLife), incorporated on January 19, 1984, is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Firm operates in two divisions: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.